Login to Your Account



Bypass, Despite 'IPASS'

AstraZeneca Concedes NSCLC Drug Iressa in U.S. Withdrawal

By Jennifer Boggs
Managing Editor

Tuesday, May 29, 2012

Amid last month's hoopla surrounding AstraZeneca plc's $1.26 billion acquisition of Ardea Biosciences Inc. and CEO David Brennan's decision to step down, the FDA's official withdrawal of lung cancer drug Iressa (gefitinib) was barely a blip on the radar.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription